![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Leading Proxy Advisory Firms Recommend That Discovery Labs' Stockholders Vote "FOR" Important Proposals at Annual Meeting of Stockholders
07 déc. 2010 06h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 7, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that two independent proxy advisory firms, ISS Proxy Advisory Services ("ISS") and Glass,...
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Discovery Labs Receives Nasdaq Delisting Notification Related to Minimum Bid Price and Plans to File Request for Hearing
03 déc. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 3, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced today that, on November 30, 2010, the Company received a Staff Determination letter from The...
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference
15 nov. 2010 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Nov. 15, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related...
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Discovery Labs Provides a Third Quarter 2010 Business and Financial Update
09 nov. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related...
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Discovery Labs Announces Pipeline and Business Update Conference Call
02 nov. 2010 17h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Nov. 2, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that it will be hosting a conference call on Tuesday, November 9, 2010, at 10:00 AM EST....
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Discovery Labs' KL4 Surfactant Granted Orphan Drug Designation for the Treatment of Cystic Fibrosis
01 nov. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), today announced that the Office of Orphan Products Development of the United States Food and Drug...
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Discovery Labs Announces Presentation & Key Results of Phase 2a Study of Aerosolized KL4 Surfactant in Cystic Fibrosis at the North American Cystic Fibrosis Conference
22 oct. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Oct. 22, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that the Phase 2a clinical study of aerosolized KL4 surfactant (lucinactant) in patients...
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Discovery Labs Announces Completion of Phase 2a Study of Aerosolized KL4 Surfactant in Cystic Fibrosis
15 oct. 2010 08h00 HE
|
Discovery Laboratories, Inc.
Aerosolized KL4 Surfactant Generally Safe and Well Tolerated in Phase 2a Trial – Supports Feasibility of Delivering Aerosolized KL4 Surfactant to Patients With Cystic Fibrosis
Results to be...
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
15 oct. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Oct. 15, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel synthetic surfactant and aerosol technologies for...
![Discovery Labs Logo](/news-release/logo/234081/0/234081.jpg?lastModified=12%2F09%2F2016%2023%3A06%3A46&size=2)
PharmaBio Expands Investment in Discovery Labs to Advance Surfaxin LS(TM) and Aerosurf(R) Programs
13 oct. 2010 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Oct. 13, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel synthetic surfactant and aerosol technologies for...